Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | RECQL | P46063 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | PLEC | Q15149 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 5/20 | 0.74 |
| ▸ | DRD3 | P35462 | 5/20 | 0.74 |
| ▸ | HTR2B | P41595 | 5/20 | 0.74 |
| ▸ | HTR6 | P50406 | 5/20 | 0.74 |
| ▸ | HTR2A | P28223 | 5/20 | 0.74 |
| ▸ | HTR1A | P08908 | 4/20 | 0.74 |
| ▸ | DRD4 | P21917 | 4/20 | 0.74 |
| ▸ | DRD5 | P21918 | 4/20 | 0.74 |
| ▸ | HTR1D | P28221 | 4/20 | 0.74 |
| ▸ | HTR1E | P28566 | 4/20 | 0.74 |
| ▸ | HTR7 | P34969 | 4/20 | 0.74 |
| ▸ | HRH1 | P35367 | 4/20 | 0.74 |
| ▸ | HTR5A | P47898 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10400706 | 1.00 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL10400862 | 1.00 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL26265228 | 1.00 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL31079495 | 1.00 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL30797592 | 1.00 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| Carbamic Acid SCHEMBL31692730 | 0.98 | KDM4E (0.77) | KDM4EMEN1KMT2AMAPTRECQL | |
| Methylsulfanylmethane SCHEMBL27454519 | 0.97 | KDM4E (0.76) | KDM4EMEN1KMT2AMAPTRECQL | |
| Cadaverine Tartrate SCHEMBL28748097 | 0.93 | MEN1 (0.71) | KDM4EMEN1KMT2AMAPTRECQL | |
| Cadaverine Tartrate SCHEMBL31561354 | 0.93 | MEN1 (0.71) | KDM4EMEN1KMT2AMAPTRECQL | |
| Acetamide SCHEMBL29094036 | 0.92 | KDM4E (0.74) | KDM4EMEN1KMT2AMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2026043908-A1 | COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS | ALLTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| US-20250375420-A1 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | ZYLORION HEALTH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20040077039-A1 | Modulation of secondary metabolite production by zinc binuclear... | DSM IP ASSETS B.V. (NL) | 2004-04-22 | — | — | US | claimed |
| EP-1409530-A2 | MODULATION OF SECONDARY METABOLITE PRODUCTION BY ZINC BINUCLEAR CLUSTER PROTEINS | Microbia, Inc. (US) | 2004-04-21 | — | — | EP | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| WO-2004004693-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS | COLLGEGIUM PHARMACEUTICAL (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2002024865-A2 | MODULATION OF SECONDARY METABOLITE PRODUCTION BY ZINC BINUCLEAR CLUSTER PROTEINS | MICROBIA, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| CN-1067956-A | Make the method and apparatus of nitrogen for ultra-high purity | BOC GROUP INC (US) | 1993-01-13 | — | — | CN | claimed |
| EP-0205068-B1 | LYSERGIC-ACID AMIDES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | ARZNEIMITTELWERK DRESDEN GmbH (DE) | 1992-01-02 | — | — | EP | claimed |
| EP-0095092-B1 | PROCESS FOR THE PREPARATION OF LYSERGIC ACID ESTERS | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-12-30 | — | — | EP | claimed |
| US-4524208-A | Process for the preparation of lysergic acid esters | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-06-18 | — | — | US | claimed |
| EP-0095092-A2 | Process for the preparation of lysergic acid esters | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-11-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | KDM4E 1355/4885MEN1 2211/4885KMT2A 1149/4885 |
| US-20250375420-A1 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | BDNF, NGF, PYGB | KDM4E 4566/4885MEN1 3812/4885KMT2A 4247/4885 |
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | KDM4E 1352/4885MEN1 922/4885KMT2A 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.